Skip to content
Triangle logo TriangleGet started
← Study library

NCT00335556 · CITED IN SOURCE DOCUMENTS

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2017-07-21

This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)

→

outcome · POSTED

Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors

→

outcome · POSTED

Response Rate

→

outcome · POSTED

Event Free Survival Probability

→

outcome · POSTED

Toxicity Rate

→

outcome · POSTED

Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization

→

outcome · POSTED

Frequency of TP53 Mutations

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Newly diagnosed disease of 1 of the following histologic types: * Focal anaplastic Wilms' tumor * Diffuse anaplastic Wilms' tumor * Clear cell sarcoma of the kidney * Malignant rhabdoid tumor (renal or extrarenal) * Renal cell carcinoma * Clear cell * Papillary * Renal medullary * Oncocytoid * Sarcomatoid * Chromophobe * Translocation * Collecting duct * Carcinoma associated with neuroblastoma * Renal cell carcinoma unclassified * Specimens/materials must be submitted for central review by Day 7 * Patients must begin protocol therapy on AREN0321 by Day 14 after surgery or biopsy (surgery/biopsy is Day 0), unless medically contraindicated * Karnofsky performance status (PS) must be \>= 50 for patients \> 16 years if age and Lansky PS must be \>= 50 for patients =\< 16 years of age * Patients must not have received systemic chemotherapy or radiation therapy prior to treatment on this study UNLESS they were enrolled on the AREN0532 or AREN0533 studies and received prenephrectomy chemotherapy for what was originally presumed to be favorable histology Wilms tumor; additionally, patients with pediatric RCC who previously received chemotherapy for another type of malignancy (not the RCC) or non-malignant condition may enroll on the study * Total bilirubin =\< 1.5 times upper limit of normal (ULN) for age * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\] or serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase \[ ALT\]) \< 2.5 times ULN for age * Shortening fraction of \>= 27% by echocardiogram OR ejection fraction of \>= 50% by radionuclide angiogram * Female patients of childbearing age must have a negative pregnancy test * Female patients who are lactating must agree to stop breast-feeding * Sexually active patients of childbearing potential must agree to use effective contraception * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
healthy Volunteers
false
maximum Age
29 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
    intervention Names
    1. Procedure: Conventional Surgery
    label
    Surgery
    type
    EXPERIMENTAL
  2. description
    Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
    intervention Names
    1. Drug: Doxorubicin Hydrochloride
    2. Procedure: Conventional Surgery
    3. Drug: Cyclophosphamide
    4. Drug: Etoposide
    5. Drug: Carboplatin
    6. Drug: Vincristine Sulfate
    7. Radiation: Radiation Therapy
    8. Other: Laboratory Biomarker Analysis
    label
    Treatment (UH-1)
    type
    EXPERIMENTAL
  3. description
    Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
    intervention Names
    1. Drug: Doxorubicin Hydrochloride
    2. Drug: Irinotecan Hydrochloride
    3. Procedure: Conventional Surgery
    4. Drug: Cyclophosphamide
    5. Drug: Etoposide
    6. Drug: Carboplatin
    7. Drug: Vincristine Sulfate
    8. Radiation: Radiation Therapy
    9. Other: Laboratory Biomarker Analysis
    label
    Treatment (window/UH-1)
    type
    EXPERIMENTAL
  4. description
    Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
    intervention Names
    1. Drug: Doxorubicin Hydrochloride
    2. Drug: Irinotecan Hydrochloride
    3. Procedure: Conventional Surgery
    4. Drug: Etoposide
    5. Drug: Carboplatin
    6. Drug: Vincristine Sulfate
    7. Radiation: Radiation Therapy
    8. Other: Laboratory Biomarker Analysis
    label
    Treatment (UH-2)
    type
    EXPERIMENTAL
  5. description
    Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
    intervention Names
    1. Drug: Doxorubicin Hydrochloride
    2. Procedure: Conventional Surgery
    3. Drug: Cyclophosphamide
    4. Drug: Etoposide
    5. Drug: Vincristine Sulfate
    6. Radiation: Radiation Therapy
    7. Other: Laboratory Biomarker Analysis
    label
    Treatment (regimen I)
    type
    EXPERIMENTAL
  6. description
    Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
    intervention Names
    1. Drug: Doxorubicin Hydrochloride
    2. Procedure: Conventional Surgery
    3. Biological: Dactinomycin
    4. Drug: Vincristine Sulfate
    5. Radiation: Radiation Therapy
    6. Other: Laboratory Biomarker Analysis
    label
    Treatment (regimen DD-4A)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (UH-2)
    3. Treatment (regimen DD-4A)
    4. Treatment (regimen I)
    5. Treatment (window/UH-1)
    description
    Given IV
    name
    Doxorubicin Hydrochloride
    type
    DRUG
  2. arm Group Labels
    1. Treatment (UH-2)
    2. Treatment (window/UH-1)
    description
    Given IV
    name
    Irinotecan Hydrochloride
    type
    DRUG
  3. arm Group Labels
    1. Surgery
    2. Treatment (UH-1)
    3. Treatment (UH-2)
    4. Treatment (regimen DD-4A)
    5. Treatment (regimen I)
    6. Treatment (window/UH-1)
    description
    Patients undergo resection
    name
    Conventional Surgery
    other Names
    1. surgery, conventional
    type
    PROCEDURE
  4. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (regimen I)
    3. Treatment (window/UH-1)
    description
    Given IV
    name
    Cyclophosphamide
    type
    DRUG
  5. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (UH-2)
    3. Treatment (regimen I)
    4. Treatment (window/UH-1)
    description
    Given IV
    name
    Etoposide
    other Names
    1. Lastet
    type
    DRUG
  6. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (UH-2)
    3. Treatment (window/UH-1)
    description
    Given IV
    name
    Carboplatin
    type
    DRUG
  7. arm Group Labels
    1. Treatment (regimen DD-4A)
    description
    Given IV
    name
    Dactinomycin
    other Names
    1. Lyovac Cosmegen
    type
    BIOLOGICAL
  8. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (UH-2)
    3. Treatment (regimen DD-4A)
    4. Treatment (regimen I)
    5. Treatment (window/UH-1)
    description
    Given IV
    name
    Vincristine Sulfate
    other Names
    1. Kyocristine
    2. Oncovin
    3. VCR
    4. Vincasar
    type
    DRUG
  9. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (UH-2)
    3. Treatment (regimen DD-4A)
    4. Treatment (regimen I)
    5. Treatment (window/UH-1)
    description
    Undergo radiotherapy
    name
    Radiation Therapy
    other Names
    1. Cancer Radiotherapy
    2. Irradiate
    3. Irradiated
    4. Irradiation
    5. RT
    type
    RADIATION
  10. arm Group Labels
    1. Treatment (UH-1)
    2. Treatment (UH-2)
    3. Treatment (regimen DD-4A)
    4. Treatment (regimen I)
    5. Treatment (window/UH-1)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
291
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Compare the outcome of patients treated with alternating CyCE/VDCy chemotherapy (with or without vincristine/irinotecan cycles) to a fixed outcome based on that seen for similar patients treated with NWTS-5 (NCT00002610).
    measure
    Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)
    time Frame
    4 years
  2. description
    The outcome of these patients will be compared with a fixed outcome based on that seen for similar patients treated with NWTS-5 regimen (NCT00002610).
    measure
    Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors
    time Frame
    4 years
  3. description
    Criteria for response assessed by three-dimensional measurement: Complete Response (CR), Disappearance of all index lesions and non-index lesions. No new lesions; Partial Response (PR), At least a 65% decrease in the sum of the volumes of the index lesions. No new lesions; Response rate (RR) = CR+PR of patients who received window therapy.
    measure
    Response Rate
    time Frame
    Up to 2 months
  4. description
    Event-free survival will be informally compared to that seem for similar patients treated on NWTS-5 (NCT00002610).
    measure
    Event Free Survival Probability
    time Frame
    4 years
  5. description
    Percentage of participants with Grade 4 cardiac toxicities, Grade 4 Sinusoidal Obstruction Syndrome (SOS), and treatment-related deaths determined using CTCAE v4.
    measure
    Toxicity Rate
    time Frame
    Up to 4 years
secondary Outcomes
  1. measure
    Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization
    time Frame
    At baseline
  2. measure
    Frequency of TP53 Mutations
    time Frame
    At baseline
Full study description
brief Summary
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
detailed Description
PRIMARY OBJECTIVES: I. Evaluate whether a treatment regimen containing cyclophosphamide, carboplatin, and etoposide alternating with vincristine, doxorubicin hydrochloride, and cyclophosphamide (regimen UH-1) improves the event-free and overall survival of patients with diffuse anaplastic Wilms' tumor (DAWT) as compared to historical controls. II. Evaluate, in a phase II "window" study, the antitumor activity of a combination of vincristine and protracted-schedule irinotecan hydrochloride in patients with metastatic DAWT. III. Evaluate whether regimen UH-1 improves the event-free and overall survival of patients with malignant rhabdoid tumor (MRT) as compared to historical controls. IV. Maintain the excellent event-free survival of patients with stage I clear cell sarcoma of the kidney (CCSK) without the use of abdominal irradiation. SECONDARY OBJECTIVES: I. Describe the outcomes of patients with stage I DAWT or stages I-III focal anaplastic Wilms' tumor (FAWT) treated with vincristine, dactinomycin, doxorubicin hydrochloride, and flank radiation. II. Describe the outcomes of patients with stage IV FAWT or stage IV CCSK treated with regimen UH-1. III. Describe event-free and overall survival of children and adolescents with localized renal cell carcinoma (RCC) (including patients with local lymph node involvement) treated with surgical resection without adjuvant therapy. IV. Describe response rate, event-free survival, and overall survival of patients with unresectable or distantly metastatic RCC treated according to institutional preference. V. Correlate histologic and molecular cytogenetic findings with outcome in pediatric RCC. VI. Evaluate the frequency of germline and inherited INI1 mutations in renal and extrarenal MRT and correlate the presence of detectable INI1 mutation with clinical outcome. VII. Determine the frequency of TP53 mutations in anaplastic Wilms' tumor and correlate the presence of detectable TP53 mutation with clinical outcome. OUTLINE: This is a multicenter study. Patients are assigned to 1 of 6 treatment regimens according to tumor histology, stage of disease, and response to treatment. SURGERY (renal cell carcinoma \[RCC\]): Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice. REGIMEN UH-1 (stage II-III or stage IV \[with no measurable disease\] diffuse anaplastic Wilms' tumor \[DAWT\], stage I-IV malignant rhabdoid tumor \[MRT\], stage IV focal anaplastic Wilms' tumor \[FAWT\], or stage IV clear cell sarcoma of the kidney \[CCSK\]): Patients receive vincristine IV on day 1 in weeks 1-3, 10-12, 13-15, 22-24, and 28-30; doxorubicin hydrochloride IV over 15 minutes on day 1 and cyclophosphamide (CPM2) IV over 15-30 minutes on day 1 in weeks 1, 10, 13, 22, and 28; and cyclophosphamide (at lower doses \[CPM1\]) IV over 1 hour and etoposide IV over 1 hour on days 1-4 and carboplatin IV over 1 hour on day 1 in weeks 4, 7, 16, 19, and 25. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable CCSK receive no further study therapy. IRINOTECAN/VINCRISTINE WINDOW THERAPY\* (stage IV DAWT with measurable disease at diagnosis): Patients receive vincristine IV on day 1 and irinotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 2. Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2. NOTE: \*Patients who are eligible for but who are unwilling to receive window therapy, receive therapy on regimen UH-1. REGIMEN UH-2 (DAWT with CR/PR to irinotecan hydrochloride/vincristine window therapy): Patients receive vincristine on day 1 in weeks 1-3, 10, 11, 16-21, 25, 26, 28-30, and 34-36 and doxorubicin hydrochloride and CPM2 as in regimen UH-1 in weeks 1, 16, 19, 28, and 34. Patients also receive CPM1, etoposide, and carboplatin as in regimen UH-1 in weeks 4, 7, 13, 22, and 31 and irinotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 10, 11, 25, and 26. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7. REGIMEN I (stage I-III CCSK): Patients receive vincristine IV on day 1 in weeks 1-3, 5-9, 8-9, 11-14, 19, and 25; doxorubicin hydrochloride IV over 15 minutes on day 1 and cyclophosphamide IV over 1 hour on days 1-3 in weeks 1, 7, 13, 19, and 25; and cyclophosphamide IV and etoposide IV on days 1-5 in weeks 4, 10, 16, and 22. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. REGIMEN DD-4A (stage I DAWT or stages I-III FAWT): Patients receive dactinomycin IV over 1-5 minutes on day 1 in weeks 1, 7, 13, 19, and 25; vincristine IV on day 1 in weeks 1-10, 13, 16, 19, 22, and 25; and doxorubicin hydrochloride IV over 15 minutes on day 1 in weeks 4,10, 16, and 22. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for at least 3 years.
Source references
references
  1. citation
    Benedetti DJ, Renfro LA, Tfirn I, Daw NC, Kalapurakal JA, Ehrlich PF, Khanna G, Perlman E, Warwick A, Gow KW, Paulino AC, Seibel NL, Grundy P, Fernandez CV, Geller JI, Mullen EA, Dome JS. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. Cancer. 2024 Jul 1;130(13):2361-2371. doi: 10.1002/cncr.35266. Epub 2024 Feb 23.
    pmid
    38396300
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-5f37af6053cc16e301a3
      requested nct id
      NCT00335556
      primary nct id
      NCT00335556
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      7560562e3838a569c94818184be048e24ff1d3f34994727e28e5a8e47d66f28e
      payload sha256
      b62e9e512f893bf0048e5649f9a8db51052acc1b80bbee1025f196f5e444d372
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-5f37af6053cc16e301a3
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00335556
      occurrences
      1. context exact
        fractions and is used to treat diffuse spill or peritoneal metastasis.[<a href="#cit/section_2.264">264</a>]</li><li>In the closed COG <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, the radiation therapy dose to the tumor bed was 10.8 Gy in 1.8-Gy fractions, with the exception of patients with stage III d
        end
        199064
        exact text
        NCT00335556
        start
        199053
      2. context exact
        o treat diffuse spill or peritoneal metastasis.[<a href="#cit/section_2.264">264</a>]</li><li>In the closed COG <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, the radiation therapy dose to the tumor bed was 10.8 Gy in 1.8-Gy fractions, with the exception of patients with stage III diffuse anaplasia, where
        end
        199087
        exact text
        NCT00335556
        start
        199076
      3. context exact
        tabindex="-1">Evidence (treatment of anaplastic stage I Wilms tumor):</p> <div class="pdq-content-list"><ol id="_2003"><li>The <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study demonstrated that outcomes for patients with stage I anaplastic Wilms tumor were improved with the addition of doxorubicin an
        end
        214742
        exact text
        NCT00335556
        start
        214731
      4. context exact
        (treatment of anaplastic stage I Wilms tumor):</p> <div class="pdq-content-list"><ol id="_2003"><li>The <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study demonstrated that outcomes for patients with stage I anaplastic Wilms tumor were improved with the addition of doxorubicin and flank radiation thera
        end
        214765
        exact text
        NCT00335556
        start
        214754
      5. context exact
        lspan="4"><span class="sup">e</span>For more information, see the <a href="/clinicaltrials/NCT00379340">AREN0533 (NCT00379340)</a> and <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> studies.</td> </tr> </TFoot> <tbody> <tr> <td>FH (with isolated
        end
        236501
        exact text
        NCT00335556
        start
        236490
      6. context exact
        sup">e</span>For more information, see the <a href="/clinicaltrials/NCT00379340">AREN0533 (NCT00379340)</a> and <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> studies.</td> </tr> </TFoot> <tbody> <tr> <td>FH (with isolated lung nodules)</td>
        end
        236524
        exact text
        NCT00335556
        start
        236513
      7. context exact
        "> <h5 id="_2009_toc">Treatment of stage IV diffuse anaplastic Wilms tumor</h5> <p id="_1965" tabindex="-1">In the <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, the combination of vincristine and irinotecan (VI) was tested in an up-front window for patients with diffuse anaplastic Wil
        end
        257188
        exact text
        NCT00335556
        start
        257177
      8. context exact
        009_toc">Treatment of stage IV diffuse anaplastic Wilms tumor</h5> <p id="_1965" tabindex="-1">In the <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, the combination of vincristine and irinotecan (VI) was tested in an up-front window for patients with diffuse anaplastic Wilms tumor and measurabl
        end
        257211
        exact text
        NCT00335556
        start
        257200
      9. context exact
        diffuse anaplastic Wilms tumors. This trial will expand on the overall improvement observed with the revised UH1/UH2 regimen from the <a href="/clinicaltrials/NCT00335556">AREN0321</a> trial, which was modified along with the addition of vincristine/irinotecan.</li></ul></div> <section id="_TrialSearch_986_sid_6">
        end
        259869
        exact text
        NCT00335556
        start
        259858
      10. context exact
        n studies of rhabdoid tumor of the kidney:</p> <div class="pdq-content-list"><ol id="_1301"><li>In the Children's Oncology Group <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, patients with rhabdoid tumor of the kidney or malignant rhabdoid tumor were treated with regimen UH1 or dose-reduced revised
        end
        540312
        exact text
        NCT00335556
        start
        540301
      11. context exact
        umor of the kidney:</p> <div class="pdq-content-list"><ol id="_1301"><li>In the Children's Oncology Group <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, patients with rhabdoid tumor of the kidney or malignant rhabdoid tumor were treated with regimen UH1 or dose-reduced revised UH1, which included al
        end
        540335
        exact text
        NCT00335556
        start
        540324
      12. context exact
        index="-1">Evidence (surgery, chemotherapy, and radiation therapy):</p> <div class="pdq-content-list"><ol id="_828"><li>In the <a href="/clinicaltrials/NCT00335556">AREN0321 (NCT00335556)</a> study, patients (n = 82) with stages I, II, and III disease were treated with regimen I, which consisted of vincristine, doxorubic
        end
        570287
        exact text
        NCT00335556
        start
        570276
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/21c44e98d92c4ee887.html
      source file sha256
      7560562e3838a569c94818184be048e24ff1d3f34994727e28e5a8e47d66f28e
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:51.520868+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      dcea2437ffe21206fe0448d1b99b68926b02cc4dd28e304c48dca82a54bfd1fb
      source title
      Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 15, 2025
        datetime
        2025-04-15T12:00:00Z
        display
        April 15, 2025

    Preserved source evidence · Not medical advice